In a video interview, Dr. Thomas Grace, Medical Director at the Blanchard Valley Diabetes Center in Findlay, Ohio, describes the clinical utility of using rtCGM in a primary care setting and the steps taken to implement a rtCGM-centered management program in his clinic. Dr. Grace also details the expansion of the rtCGM program to employees with diabetes, implemented through a partnership with a locally based Fortune 500 company. If you are a health plan care manager or if your role involves population health management, you won’t want to miss the progressive, value-driven approach shared by Dr. Grace and the ROI derived from rtCGM data and enhanced patient experience.
As part of a new series of video resources hosted on ManagedCareCGM.com, Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP), offers her insights on progressive approaches to diabetes coverage and management. She shares HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level and enhanced access among patients with diabetes who are prescribed any insulin or ≥3 non-insulin medications. Findings from the MOBILE study—on which Ms. Kruger served as an investigator/author—are also detailed, including the benefits associated with real-time CGM (rtCGM) in type 2 diabetes (T2D) for improving glycemic control and meeting quality measures; these findings were particularly noteworthy considering a racially and ethnically diverse study population representing traditionally underserved demographics of patients. A post hoc analysis from MOBILE is likewise discussed, along with its implications for using rtCGM to improve T2D management among Medicare beneficiaries.
Expert: Thomas Danne, MD, Professor of Pediatrics, Children’s Hospital Auf der Bult, Hanover, Germany
International Consensus on Use of Continuous Glucose Monitoring
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Going Beyond A1c – One Outcome Can’t Do It All
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Continuous Glucose Monitoring in Adults with Type 1 Diabetes: Real-World Data from the German/Austrian Prospective Diabetes Follow-Up Registry
Acceptability and Utilization of Newer Technologies and Effects on Glycemic Control in Type 2 Diabetes: Lessons Learned from Lockdown
Blood Glucose Control During Lockdown for COVID-19: CGM Metrics in Italian Adults With Type 1 Diabetes
Personal Experience With COVID-19 and Diabetes in the South of France: Technology Facilitates the Management of Diabetes in Disruptive Times